On Oct 28, major Wall Street analysts update their ratings for $HCA Healthcare (HCA.US)$, with price targets ranging from $396 to $460.
Morgan Stanley analyst Craig Hettenbach maintains with a hold rating, and adjusts the target price from $427 to $406.
Barclays analyst Andrew Mok CFA maintains with a buy rating, and maintains the target price at $396.
TD Cowen analyst Ryan Langston maintains with a buy rating, and adjusts the target price from $450 to $440.
RBC Capital analyst Ben Hendrix maintains with a buy rating, and maintains the target price at $405.
Truist Financial analyst David S Macdonald maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:
The performance of HCA Healthcare was anticipated to encounter disruptions due to hurricanes. A 'bigger surprise', however, was the projection for EBITDA and EPS in 2025, which fell below market expectations and ended a streak of strong financial outperformances. Despite the allure of the stock's recent 9% decline, there is a belief that it may enter a phase of consolidation.
HCA Healthcare's third-quarter results demonstrated resilience, overcoming the negative impacts of hurricanes, which are anticipated to persist into the fourth quarter and push full-year 2024 guidance towards the lower end. Despite these ongoing challenges, the company's management anticipates earnings growth in 2025 to meet or exceed its long-term objectives, supported by an admissions growth forecast of 3%-4%, which is considered above the usual trend.
The firm revised its model after evaluating HCA Healthcare's third-quarter results. Despite high anticipations for the quarter, the company delivered a robust underlying performance, evidenced by a 7.1% increase in same-store revenues compared to the previous year's third-quarter comparison of 7.9%.
HCA Healthcare's Q3 results aligned with market expectations, influenced by solid same-store volumes and increased Medicaid DPPs, which balanced out the interruptions caused by hurricanes. Following the earnings announcement, the company's stock experienced a significant drop, which is thought to be a result of projected EBITDA for 2025 slightly trailing market estimates, a market shift in anticipation of the upcoming election, and a perception of high valuation.
Here are the latest investment ratings and price targets for $HCA Healthcare (HCA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月28日，多家華爾街大行更新了$HCA醫療 (HCA.US)$的評級，目標價介於396美元至460美元。
摩根士丹利分析師Craig Hettenbach維持持有評級，並將目標價從427美元下調至406美元。
巴克萊銀行分析師Andrew Mok CFA維持買入評級，維持目標價396美元。
TD Cowen分析師Ryan Langston維持買入評級，並將目標價從450美元下調至440美元。
加皇資本市場分析師Ben Hendrix維持買入評級，維持目標價405美元。
儲億銀行分析師David S Macdonald維持買入評級。
此外，綜合報道，$HCA醫療 (HCA.US)$近期主要分析師觀點如下：
hca醫療的表現預計會因颶風遭遇中斷。然而，2025年EBITDA和每股收益的預測卻出乎意料地低於市場預期，終結了一系列強勁的財務表現。儘管該股最近下跌了9%，但有人認爲它可能進入一段整固期。
hca醫療的第三季度業績表現出色，克服了颶風的負面影響，預計負面影響將持續到第四季度，並將2024年全年指引拉向較低端。儘管面臨持續挑戰，公司管理層預計2025年收入增長將達到或超過長期目標，得益於3%-4%的入院增長預測，這被認爲高於通常趨勢。
該公司在評估了hca醫療第三季度的業績後進行了模型修訂。儘管對本季度寄予厚望，但公司交出了強勁的基本業績，同店銷售收入相比去年同期增長了7.1%，而去年同期的增長率爲7.9%。
hca醫療的第三季度業績符合市場預期，受到實體店同店銷售量的穩固支撐以及醫療補助計劃（Medicaid DPPs）增加的影響，平衡了颶風造成的中斷。在盈利公告後，該公司股票經歷了大幅下跌，這被認爲是2025年EBITDA略低於市場預期、市場在預期即將到來的選舉而發生轉變、以及高估值感知的結果。
以下爲今日6位分析師對$HCA醫療 (HCA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
